ARTICLE | Clinical News
Apeptico reports Phase II data for pulmonary product
April 10, 2014 12:05 AM UTC
Apeptico Forschung und Entwicklung GmbH (Vienna, Austria) said orally inhaled AP301 led to earlier onset and "more pronounced activation" of pulmonary edema clearance vs. placebo in a Phase IIa trial ...